For example, PLGA NBs have been conjugated with cancer-targeting ligands such as a humanized antibody to target the overexpressed TAG-72 antigen . NB-assisted dual-mode imaging was demonstrated on a gelatin phantom with multiple embedded tumor simulators at different NB concentrations, demonstrating the feasibility of using dual-mode contrast agents for cancer targeting and simultaneous fluorescence/US imaging. Another PLGA-PEG NP recently described coupled the J591 monoclonal antibody to its surface in order to direct targeting towards PSMA-expressing prostate cancer cells. A pDNA encoding β-gal was Inhibitors,research,lifescience,medical complexed to this NP via a salicyl-hydroxamic-acid- (SHA-) derivatized PEI. After
encapsulation, an 8- to 10-fold enhancement in gene expression was attained due to enhanced specific internalization and uptake of the complex in PSMA-expressing cells. The release of pDNA from NP showed a small initial burst release followed by a 5% release over
48h. The release accelerated thereafter and ~60% was released within a month. Also, the PEG-PLGA composition Inhibitors,research,lifescience,medical (triblock polymer) was found to enhance the polyplex/microparticle localization to the cell nucleus and this enhanced the endocytic process of J591-mediated targeting in prostate cancer cells. RGD. Another class of polymeric contrast agents with targeting potential was described in which the Arg-Gly-Asp Inhibitors,research,lifescience,medical (RGD) peptide sequence was conjugated to either PLA or PLGA microcapsules [72, 73]. These hollow, biodegradable microcapsules targeted αvβ3 and αvβ5 integrins, typically expressed during angiogenesis. In vitro results indicated that the modified capsules remained echogenic and adhered specifically Inhibitors,research,lifescience,medical to the breast cancer cell line MDA-MB-231. An interesting modification of
this approach has been utilization of a cyclic RGD targeting moiety conjugated via a micelle-type PLGA-4 arm-PEG branched polymer for detecting and treating pancreatic cancer . These NPs contained the 4-arm PEG as a corona Inhibitors,research,lifescience,medical and PLGA as a core, while the particle surface was conjugated with cRGD for in vivo tumor targeting. The hydrodynamic size of NP was ~150–180nm and NIR microscopy and flow cytometry studies showed that the cRGD-conjugated NPs were taken up more efficiently by U87MG glioma cells overexpressing integrins. Whole-body imaging showed that the cRGD NP had the highest accumulation in pancreatic tumors at 48h after-injection with low in vivo toxicity. We would predict additional receptor else targeting will be attempted in the near future and this will AZD5363 price likely extend targeting of PLGA nanoparticles to the VEGFR and EGFR family of receptors to achieve enhanced drug and gene delivery, as already has been shown to work for microbubbles targeting the VEGFR2 receptor in tumor-associated endothelial cells [75, 76]. Proapoptotic. PLGA NPs coated with a proapoptotic monoclonal antibody have been efficient in delivering drugs in a targeted manner.